Effect of Roux-en-Y Gastric Bypass with Different Lengths of Biliopancreatic and Alimentary Limbs for Patients with Type 2 Diabetes Mellitus and a BMI < 35 kg/m


Journal

Obesity surgery
ISSN: 1708-0428
Titre abrégé: Obes Surg
Pays: United States
ID NLM: 9106714

Informations de publication

Date de publication:
11 2021
Historique:
received: 05 01 2021
accepted: 11 08 2021
revised: 07 08 2021
pubmed: 18 8 2021
medline: 26 10 2021
entrez: 17 8 2021
Statut: ppublish

Résumé

There have been no definite conclusions about the biliopancreatic limb (BPL) and alimentary limb (AL) lengths in Roux-en-Y gastric bypass (RYGB) operations for different populations and BMIs. Western scholars have performed many studies on the lengths of the BPL and AL in patients with a BMI ≥ 35 kg/m Clinical data were collected prospectively and analyzed retrospectively for 87 patients with type 2 diabetes (T2DM) who underwent RYGB with a BPL of 50 cm and an AL of 50 cm (BPL50/AL50) or with a BPL of 100 cm and an AL of 100 cm (BPL100/AL100) and who were followed up for 5 years. The cohort included 42 patients in the BPL50/AL50 group and 45 patients in the BPL100/AL100 group. At 5 years, there were significant differences in BMI, total weight loss (TWL%), glycosylated hemoglobin, and homeostasis model assessment insulin resistance between BPL50/AL50 and BPL100/AL100 (P < 0.05). Diabetes remission rate of the BPL100/AL100 group was significantly higher than that of the BPL50/AL50 group. Diabetes remission at 1 year after surgery correlated with the length limb (BPL + AL), duration of diabetes and TWL%. There was no difference in complications between BPL50/AL50 and BPL100/AL100. RYGB with BPL100/AL100 is a safe and effective treatment for diabetic patients with a BMI < 35 kg/m

Identifiants

pubmed: 34403077
doi: 10.1007/s11695-021-05658-6
pii: 10.1007/s11695-021-05658-6
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4877-4884

Informations de copyright

© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Chooi YC, Ding C, Magkos F. The epidemiology of obesity. Metabolism. 2019;92:6–10.
doi: 10.1016/j.metabol.2018.09.005
Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Aminian A, Brethauer SA, et al. Bariatric surgery versus intensive medical therapy for diabetes—5-year outcomes. New Engl J Med. 2017;376(7):641–51.
doi: 10.1056/NEJMoa1600869
Madan AK, Harper JL, Tichansky DS. Techniques of laparoscopic gastric bypass: on-line survey of American Society for Bariatric Surgery practicing surgeons. Surg Obes Relat Dis. 2008;4(2):166–72 (discussion 72-3).
doi: 10.1016/j.soard.2007.08.006
Brolin RE, Kenler HA, Gorman JH, Cody RP. Long-limb gastric bypass in the superobese. A prospective randomized study. Ann Surg. 1992;215(4):387–95.
doi: 10.1097/00000658-199204000-00014
Dogan K, Homan J, Aarts EO, van Laarhoven CJ, Janssen IM, Berends FJ. A short or a long Roux limb in gastric bypass surgery: does it matter? Surg Endosc. 2017;31(4):1882–90.
doi: 10.1007/s00464-016-5188-z
Homan J, Boerboom A, Aarts E, Dogan K, van Laarhoven C, Janssen I, et al. A longer biliopancreatic limb in Roux-en-Y gastric bypass improves weight loss in the first years after surgery: results of a randomized controlled trial. Obes Surg. 2018;28(12):3744–55.
doi: 10.1007/s11695-018-3421-7
MacLean LD, Rhode BM, Nohr CW. Long- or short-limb gastric bypass? J Gastrointest Surg. 2001;5(5):525–30.
doi: 10.1016/S1091-255X(01)80091-3
Kraljević M, Süsstrunk J, Köstler T, Lazaridis II, Zingg U, Delko T. Short or long biliopancreatic limb bypass as a secondary procedure after failed laparoscopic sleeve gastrectomy. Obes Surg. 2021;31(1):170–8.
doi: 10.1007/s11695-020-04868-8
Kaska L, Kobiela J, Proczko M, Stefaniak T, Sledziński Z. Does the length of the biliary limb influence medium-term laboratory remission of type 2 diabetes mellitus after Roux-en-Y gastric bypass in morbidly obese patients? Wideochir Inne Tech Maloinwazyjne. 2014;9(1):31–9.
pubmed: 24729807 pmcid: 3983547
Murad AJ Jr, Cohen RV, de Godoy EP, Scheibe CL, Campelo GP, Ramos AC, et al. A prospective single-arm trial of modified long biliopancreatic and short alimentary limbs Roux-En-Y gastric bypass in type 2 diabetes patients with mild obesity. Obes Surg. 2018;28(3):599–605.
doi: 10.1007/s11695-017-2933-x
Ruiz-Tovar J, Vorwald P, Gonzalez-Ramirez G, Posada M, Salcedo G, Llavero C, et al. Impact of biliopancreatic limb length (70 cm vs 120 cm), with constant 150 cm alimentary limb, on long-term weight loss, remission of comorbidities and supplementation needs after Roux-En-Y gastric bypass: a prospective randomized clinical trial. Obes Surg. 2019;29(8):2367–72.
doi: 10.1007/s11695-019-03717-7
American Diabetes A. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S13-S27.
Nguyen NT, Varela JE. Bariatric surgery for obesity and metabolic disorders: state of the art. Nat Rev Gastroenterol Hepatol. 2017;14(3):160–9.
doi: 10.1038/nrgastro.2016.170
Pareek M, Schauer PR, Kaplan LM, Leiter LA, Rubino F, Bhatt DL. Metabolic surgery: weight loss, diabetes, and beyond. J Am Coll Cardiol. 2018;71(6):670–87.
doi: 10.1016/j.jacc.2017.12.014
Yabe D, Seino Y, Fukushima M, Seino S. beta cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East Asians. Curr Diab Rep. 2015;15(6):602.
doi: 10.1007/s11892-015-0602-9
Qian L, Xu L, Wang X, Fu X, Gu Y, Lin F, et al. Early insulin secretion failure leads to diabetes in Chinese subjects with impaired glucose regulation. Diabetes Metab Res Rev. 2009;25(2):144–9.
doi: 10.1002/dmrr.922
Orci L, Chilcott M, Huber O. Short versus long Roux-limb length in Roux-en-Y gastric bypass surgery for the treatment of morbid and super obesity: a systematic review of the literature. Obes Surg. 2011;21(6):797–804.
doi: 10.1007/s11695-011-0409-y
Taylor JD, Leitman IM, Rosser J, Davis B, Goodman E. Does the position of the alimentary limb in Roux-en-Y gastric bypass surgery make a difference? J Gastrointest Surg. 2006;10(10):1397–9.
doi: 10.1016/j.gassur.2006.09.007
Smelt HJM, Van Rijn S, Pouwels S, Aarts MPW, Smulders JF. The influence of different alimentary and biliopancreatic limb lengths in gastric bypass patients. Obes Surg. 2021;31(2):481–9.
doi: 10.1007/s11695-020-05028-8
Boerboom A, Homan J, Aarts E, Aufenacker T, Janssen I, Berends F. A long biliopancreatic and short alimentary limb results in more weight loss in revisional RYGB surgery. Outcomes of the randomized controlled ELEGANCE REDO trial. Surg Obes Relat Dis. 2019;15(1):60–69.
Nora M, Guimaraes M, Almeida R, Martins P, Goncalves G, Freire MJ, et al. Metabolic laparoscopic gastric bypass for obese patients with type 2 diabetes. Obes Surg. 2011;21(11):1643–9.
doi: 10.1007/s11695-011-0418-x
Murad AJ Jr, Cohen RV, de Godoy EP, Scheibe CL, Campelo GP, Ramos AC, et al. A prospective single-arm trial of modified long biliopancreatic and short alimentary limbs Roux-En-Y gastric bypass in type 2 diabetes patients with mild obesity. Obes Surg. 2018;28(3):599–605.
doi: 10.1007/s11695-017-2933-x
Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Nanni G, et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet. 2015;386(9997):964–73.
doi: 10.1016/S0140-6736(15)00075-6
Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Capristo E, et al. Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial. Lancet. 2021;397(10271):293–304.
doi: 10.1016/S0140-6736(20)32649-0
Lee WJ, Chong K, Chen CY, Chen SC, Lee YC, Ser KH, et al. Diabetes remission and insulin secretion after gastric bypass in patients with body mass index <35 kg/m
doi: 10.1007/s11695-011-0401-6
Courcoulas AP, Gallagher JW, Neiberg RH, Eagleton EB, DeLany JP, Lang W, et al. Bariatric Surgery vs Lifestyle Intervention for Diabetes Treatment: 5-Year Outcomes From a Randomized Trial. J Clin Endocrinol Metab. 2020;105(3):866–76.
doi: 10.1210/clinem/dgaa006
Patrício BG, Morais T, Guimarães M, Veedfald S, Hartmann B, Hilsted L, et al. Gut hormone release after gastric bypass depends on the length of the biliopancreatic limb. Int J Obes (Lond). 2019;43(5):1009–18.
doi: 10.1038/s41366-018-0117-y
Goh YM, Toumi Z, Date RS. Surgical cure for type 2 diabetes by foregut or hindgut operations: a myth or reality? A systematic review Surg Endosc. 2017;31(1):25–37.
doi: 10.1007/s00464-016-4952-4
Palha AM, Pereira SS, Costa MM, Morais T, Maia AF, Guimaraes M, et al. Differential GIP/GLP-1 intestinal cell distribution in diabetics’ yields distinctive rearrangements depending on Roux-en-Y biliopancreatic limb length. J Cell Biochem. 2018;119(9):7506–14.
doi: 10.1002/jcb.27062
Nora M, Morais T, Almeida R, Guimarães M, Monteiro MP. Should Roux-en-Y gastric bypass biliopancreatic limb length be tailored to achieve improved diabetes outcomes? Medicine (Baltimore). 2017;96(48):e8859.
Lee WJ, Hur KY, Lakadawala M, Kasama K, Wong SK, Chen SC, et al. Predicting success of metabolic surgery: age, body mass index, C-peptide, and duration score. Surg Obes Relat Dis. 2013;9(3):379–84.
doi: 10.1016/j.soard.2012.07.015
Lee MH, Lee WJ, Chong K, Chen JC, Ser KH, Lee YC, et al. Predictors of long-term diabetes remission after metabolic surgery. J Gastrointest Surg. 2015;19(6):1015–21.
doi: 10.1007/s11605-015-2808-1
Park JY, Kim YJ. Prediction of Diabetes Remission in Morbidly Obese Patients After Roux-en-Y Gastric Bypass. Obes Surg. 2016;26(4):749–56.
doi: 10.1007/s11695-015-1823-3
Gero D, Favre L, Allemann P, Fournier P, Demartines N, Suter M. Laparoscopic Roux-En-Y Gastric Bypass Improves Lipid Profile and Decreases Cardiovascular Risk: a 5-Year Longitudinal Cohort Study of 1048 Patients. Obes Surg. 2018;28(3):805–11.
doi: 10.1007/s11695-017-2938-5
Cunha FM, Oliveira J, Preto J, Saavedra A, Costa MM, Magalhaes D, et al. The effect of bariatric surgery type on lipid profile: an age, sex, body mass index and excess weight loss matched study. Obes Surg. 2016;26(5):1041–7.
doi: 10.1007/s11695-015-1825-1
Weale AR, Edwards AG, Bailey M, Lear PA. Intestinal adaptation after massive intestinal resection. Postgrad Med J. 2005;81(953):178–84.
doi: 10.1136/pgmj.2004.023846
Marcotte E, Chand B. Management and prevention of surgical and nutritional complications after bariatric surgery. Surg Clin N Am. 2016;96(4):843–56.
doi: 10.1016/j.suc.2016.03.006
Bal BS, Finelli FC, Shope TR, Koch TR. Nutritional deficiencies after bariatric surgery. Nat Rev Endocrinol. 2012;8(9):544–56.
doi: 10.1038/nrendo.2012.48
Gasteyger C, Suter M, Gaillard RC, Giusti V. Nutritional deficiencies after Roux-en-Y gastric bypass for morbid obesity often cannot be prevented by standard multivitamin supplementation. Am J Clin Nutr. 2008;87(5):1128–33.
doi: 10.1093/ajcn/87.5.1128
Inabnet WB, Quinn T, Gagner M, Urban M, Pomp A. Laparoscopic Roux-en-Y gastric bypass in patients with BMI < 50: a prospective randomized trial comparing short and long limb lengths. Obes Surg. 2005;15(1):51–7.
doi: 10.1381/0960892052993468

Auteurs

Xiang Gao (X)

Department of General Surgery, Third Xiangya Hospital, Central South University, Changsha, 410013, China.

Liyong Zhu (L)

Department of General Surgery, Third Xiangya Hospital, Central South University, Changsha, 410013, China.

Guohui Wang (G)

Department of General Surgery, Third Xiangya Hospital, Central South University, Changsha, 410013, China.

Weizheng Li (W)

Department of General Surgery, Third Xiangya Hospital, Central South University, Changsha, 410013, China.

Zhi Song (Z)

Department of General Surgery, Third Xiangya Hospital, Central South University, Changsha, 410013, China.

Shaihong Zhu (S)

Department of General Surgery, Third Xiangya Hospital, Central South University, Changsha, 410013, China.

Pengzhou Li (P)

Department of General Surgery, Third Xiangya Hospital, Central South University, Changsha, 410013, China. 602223@csu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH